Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): A double-blind, placebo-controlled, randomised clinical trial
Date: 2013–2015
Funding: UK NIHR HTA
Collaborator(s): Centre for Mental Health, Imperial College London, UK
Information: Judit Simon (co-PI)
The negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialization, speech, and movement. Persistent negative symptoms are held to account for much of the long-term morbidity and poor functional outcome of people with schizophrenia. This study sought to assess the potential benefit of a depression medication in this patient population. The DHE was involved in the economic evaluation of this intervention alongside the ACTIONS study.
Result(s):
- Barnes TRE, Leeson VC, Paton C, Costelloe C, Simon J, Kiss N, Osborn D, Killaspy H, Craig TKJ, Lewis S, Keown P, Ismail S, Crawford M, Baldwin D, Lewis G, Geddes J, Kumar M, Pathak R, Taylor S (2016) Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technology Assessment, 20(29). DOI: 10.3310/hta20290.